The investigation determined that a false negative vitros anti-hiv 1 + 2 (ahiv1+2) result was obtained from non-vitros riqas proficiency fluids when using vitros immunodiagnostics products vitros ahiv1+2 reagent in combination with a vitros 5600 integrated system.A definite assignable cause of the event cannot be determined with the information provided.Sample handling and storage of the proficiency samples is not a contributor to the event as it was determined that the customer is following the riqas ifu recommendation for sample handling and storage.Therefore, improper sample handling and storage is not a contributor to the event.The customer did not provide the lot number of the vitros ahiv1+2 quality control (qc) fluid used to verify the performance of the vitros ahiv1+2 assay, however, a review of the customers qc results prior to the event fell in the appropriate vitros interpretation classification, indicating acceptable accuracy when using reagent lot 4260.Vitros ahiv1+2 reagent lot 4260 was calibrated on (b)(6) 2023 and subsequently calibrated on (b)(6) 2023 indicating all results processed after (b)(6) 2023 were obtained on an expired calibration.The event occurred on (b)(6) 2023, therefore, the false negative vitros ahiv1+2 result was processed on an expired calibration.There was no evidence of an instrument malfunction, however, as no diagnostic precision testing was conducted to verify the performance of the vitros 5600 integrated system, an instrument issue cannot be completely ruled out as a contributor to the event.The customer did not indicate that any unexpected vitros ahiv1+2 results were obtained for patient samples at the time of the event or over the course of the investigation and there are no reported allegations of patient harm, however, the investigation cannot rule out that patient samples were not, or would not be affected, if the event were to occur undetected.
|